Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 28, 1998 - Issue 9
149
Views
41
CrossRef citations to date
0
Altmetric
Research Article

Effects of propofol on human hepatic microsomal cytochrome P450 activities

, , &
Pages 845-853 | Published online: 22 Sep 2008

References

  • BAILIE, G. R., COCKSHOTT, I. D., DOUGLAS, E. J. and BOWLES, B. J. M., 1992, Pharmacokinetics of propofol during and after long term continuous infusion for maintenance of sedation in ICU patients. British Journal of Anaesthesia, 68, 486–491.
  • BAKER, M. T., CHADAM, M. V. and RONNENBERG, W. C. Jr, 1993, Inhibitory effects of propofol on cytochrome P450 activities in rat hepatic microsomes. Anesthesia and Analgesia, 76, 817–821.
  • BERTZ, R. J. and GRANNEMAN, G. R., 1997, Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clinical Pharmacokinetics, 32, 210–258.
  • CHEN, T. L., UENG, T. H., CIIEN, S. H., LEE, P. H., FAN, S. Z. and Liu, C. C., 1995a, Human cytochrome P450 mono-oxygenase system is suppressed by propofol. British Journal of Anaesthesia, 74, 558–562.
  • CHEN, T. L., WANG, M. J., HUANG, C. H., Liu, CC. and UENG, T. H., 1995b, Differences between in vivo and in vitro effects of propofol on defluorination and metabolic activities of hamster hepatic cytochrome P450 mono-oxygenases. British Journal of Anaesthesia, 75, 462–466.
  • GEPTS, E., CAMU, F., COCKSHOTT, I. D. and DOUGLAS, E. J., 1987, Disposition of propofol administered as constant rate intravenous infusion in humans. Anesthesia and Analgesia, 66, 1256–1263.
  • GEPTS, E, JoNucHEER, K, MAES, V, SONCK, W and CAMU, F., 1988, Disposition kinetics of propofol during alfentanil anaesthesia. Anaesthesia, 43 (suppl.), 8–13.
  • JANICKI, P. K., JAMES, M. F. M. and ERSKINE, W. A. R., 1992, Propofol inhibits enzymatic degradation of alfentanil and sufentanil by isolated liver microsomes in vitro. British Journal of Anaesthesia, 68, 311–312.
  • KHARASCH, E. D. and THUMMEL, K., 1993, Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance ?Anesthesia and Analgesia, 76, 1033–1039.
  • KRONBACH, T., FISCHER, V. and MEYER, U. A., 1988, Cyclosporine metabolism in human liver: Identification of a cytochrome P450IIIA gene family as the major cyclosporine-metabolising enzyme explains interactions of cyclosporine with other drugs. Clinical Pharmacology and Therapeutics, 43, 630–635.
  • LABROO, R. B., THUMMEL, K. E., KUNZE, K. L., PODOLL, T., TRAGER, W. F. and KHARASCH, E. D., 1995, Catalytic role of cytochrome P450 3A4 in multiple pathways of alfentanil metabolism. Drug Metabolism and Disposition, 23, 490–496.
  • LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the folin phenol reagent. Journal of Biological Chemistry, 193, 165–175.
  • MAITRE, P. O., VOZEH, S., HEYKANTS, J., THOMSON, D. A. and STANSKI, D. R., 1987, Population pharmacokinetics of alfentanil: the average dose-plasma concentration relationship and inter-individual variability in patients. Anesthesiology, 66, 13–16.
  • McKILLOP, D., 1985, Effects of phenobarbitone and )3-naphthoflavone on hepatic microsomal drug metabolising enzymes of the male beagle dog. Biochemical Pharmacology, 34, 3137–3142.
  • NELSON, D. R., KAMATAKI, T., WAXMAN, D. J., GUENGERICH, F. P., ESTABROOK, R. W., FEYEREISEN, GONZALEZ, F. J., COON, M. J., GUNSALUS I. C., GOTOH, 0., OKUDA, K. and NEBERT, D. W., 1993, The P450 superfamily : Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA and Cell Biology, 12, 1–51.
  • PERTEK, J. P., CHAOUI, K., JuNKE, E., ARTIS, M., COISSARD, A., FRISONI, A. and MEISTELMAN, C., 1996, Effets du propofol sur les concentrations sanguines de ciclosporine. Annales Francaises d' Anesthesie et de Reanimation, 15, 589–594 (English abstract).
  • RING, B. J., BINKLEY, S. N., VANDENBRANDEN, M. and WRIGHTON, S. A., 1996, In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A British Journal of Clinical Pharmacology, 41, 181–186.
  • SERVIN, F., DESMONTS, J. M., HABERER, J. P., COCKSHOTT, I. D., PLUMMER, G. F. and FARINOTTI, 1988, Pharmacokinetics and protein binding of propofol in patients with cirrhosis. Anesthesiology, 69, 887–891.
  • SIMONS, P. J., COCKSHOTT, I. D., DOUGLAS, E. J., GORDON, E. A., HOPKINS, K. and ROWLAND, M., 1988, Disposition in male volunteers of a subanaesthetic intravenous dose of an oil in water emulsion of '4C-propofol. Xenobiotica, 18, 429–440.
  • SIMONS, P. J., COCKSHOTT, I. D., DOUGLAS, E. J., GORDON, E. A., KNOTT, S. and RUANE, R. J., 1991, Distribution in female rats of an anaesthetic intravenous dose of '4C-propofol. Xenobiotica, 21, 1325–1335.
  • SPATZENEGGER, M. and JAEGER, W., 1995, Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metabolism Reviews, 27, 397–417.
  • VON MOLTKE, L. L., GREENBLATT, D. J., DUAN, S. X., HARMATZ, J. S. and SHADER, R. I., 1994a, In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. Journal of Clinical Pharmacology, 34, 1222–1227.
  • VON MOLTKE, L. L., GREENBLATT, D. J., COTREAU -BIBBO, M. M., HARMATZ, J. S. and SHADER, R. I., 1994b, Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. British Journal of Clinical Pharmacology, 38, 23–31.
  • VON MOLTKE, L. L., GREENBLATT, D. J., COTREAU -BIBBO, M. M., DUAN, S. X., HARMATZ, J. S. and SHADER, R. I., 1994c, Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. Journal of Pharmacology and Experimental Therapeutics, 268, 1278–1283.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.